

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)



ATHENS MEDICAL CENTER S.A.

INTERIM FINANCIAL STATEMENTS
FOR THE PERIOD ENDED
SEPTEMBER 30, 2013

IN ACCORDANCE WITH INTERNATIONAL
FINANCIAL REPORTING STANDARDS (IFRS)

It is certified that the attached interim consolidated and separate Financial Statements for period 1st January 2013 to 30th September 2013 are those approved by the board of directors of “ATHENS MEDICAL CENTER S.A.” in November 27th 2013 and they are uploaded to the internet address: www.iatriko.gr. The records and information published to the press aim at providing to the reader some general financial records and information, but they do not provide the whole picture of the financial condition and the results of Group and the Parent Company, according to the International Financial Reporting Standards.

Georgios Apostolopoulos
President of the Board of Directors
ATHENS MEDICAL CENTER S.A.

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

CONTENTS OF INTERIM FINANCIAL STATEMENTS

	<u>Page</u>
Income Statement for the period ended September 30, 2013 and 2012	3
Comprehensive Income Statement for the period ended September 30, 2013 and 2012	4
Statements of Financial Position as of September 30, 2013, December 31, 2012 and December 31, 2011	5 – 6
Statement of Changes in Equity for the period ended September 30, 2013	7
Statement of Changes in Equity for the period ended September 30, 2012	8
Cash Flow Statement for the period ended September 30, 2013 and 2012	9
Corporate information	10
Preparation base of Financial Statements	11
Principal accounting policies	11 – 13
Risk management	13 – 16
Notes to the Financial Statements	16 - 46

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

INCOME STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER 2013 AND 2012

	Notes	The Group				The Company			
		1/1-30/9 2013	1/1-30/9 2012(*)	1/7-30/9 2013	1/7-30/9 2012(*)	1/1-30/9 2013	1/1-30/9 2012(*)	1/7-30/9 2013	1/7-30/9 2012(*)
INCOME:									
Revenue		133.273	173.815	39.913	43.464	129.728	170.046	38.789	42.333
Cost of sales		(105.438)	(129.816)	(33.669)	(35.272)	(103.997)	(126.364)	(33.196)	(34.773)
Gross Profit		27.835	43.999	6.245	8.192	25.730	43.682	5.592	7.560
Administrative expenses and Distribution Costs	7	(24.062)	(27.360)	(7.693)	(9.709)	(21.515)	(24.493)	(6.989)	(8.768)
Other income/ (expenses)	8	2.453	5.880	472	2.056	1.812	5.934	507	2.064
Net financial income/ (costs)	9	(6.528)	(8.223)	(2.014)	(2.387)	(6.700)	(8.022)	(1.978)	(2.305)
PROFIT / (LOSS) BEFORE TAX		(301)	14.295	(2.990)	(1.849)	(673)	17.101	(2.867)	(1.450)
Income Tax Expense	10	(5.339)	(5.188)	(314)	(324)	(4.965)	(5.115)	(296)	(297)
PROFIT / (LOSS) FOR THE PERIOD		(5.641)	9.107	(3.305)	(2.173)	(5.638)	11.985	(3.163)	(1.748)
Attributable to:									
Equity holders of the parent company		(5.665)	8.948	(3.321)	(2.181)	(5.638)	11.985	(3.163)	(1.748)
Non controlling Interests		24	160	16	9				
		(5.641)	9.107	(3.305)	(2.173)	(5.638)	11.985	(3.163)	(1.748)
Earnings / (losses) per Share (in Euro)									
Basic	11	(0,07)	0,10	(0,04)	(0,03)	(0,07)	0,14	(0,04)	(0,02)
Weighted average number of shares									
Basic	11	86.735.980	86.735.980	86.735.980	86.735.980	86.735.980	86.735.980	86.735.980	86.735.980

The accompanied notes and appendixes are inseparable part of the financial statements

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 SEPTEMBER 2013 AND 2012

Notes	The Group				The Company			
	1/1-30/9 2013	1/1-30/9 2012(*)	1/7-30/9 2013	1/7-30/9 2012(*)	1/1-30/9 2013	1/1-30/9 2012(*)	1/7-30/9 2013	1/7-30/9 2012(*)
Profit / (loss) for the period:	(5.641)	9.107	(3.305)	(2.173)	(5.638)	11.985	(3.163)	(1.748)
Other comprehensive income that may be reclassified subsequently to profit or loss:								
Exchange differences	20	(1)	0	(9)	0	0	0	0
Income tax relating to items of other comprehensive income	0	0	0	0	0	0	0	0
Other comprehensive income after tax (a):	20	(1)	0	(9)	0	0	0	0
Other comprehensive income that will <u>not</u> be reclassified subsequently to profit or loss:								
Recognized actuarial gains /(losses) related to provision for retirement indemnities		(1.554)		(518)		(1.536)		(512)
Income tax relating to items of other comprehensive income	(174)	311	0	104	(175)	307	0	102
Other comprehensive income after tax (b):	(174)	(1.243)	0	(414)	(175)	(1.229)	0	(410)
Total comprehensive income / (loss) after tax:	(5.795)	7.863	(3.305)	(2.597)	(5.813)	10.756	(3.163)	(2.157)
Attributable to:								
Owners of the Parent	(5.819)	7.703	(3.321)	(2.606)	(5.813)	10.756	(3.163)	(2.157)
Non controlling interests	24	160	16	9				

The accompanied notes and appendixes are inseparable part of the financial statements
(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF FINANCIAL POSITION OF 30 SEPTEMBER 2013, 31 DECEMBER 2012 AND 31 DECEMBER 2011

	Notes	The Group		
		30-September 2013	31- December 2012 (*)	31- December 2011 (*)
ASSETS				
Non current assets :				
Property, plant and equipment	12	247.352	251.798	266.527
Goodwill	13	-	-	-
Intangible assets	13	232	340	327
Investments in subsidiaries	14	-	-	-
Investments in associates consolidated by the equity method	15	348	348	352
Other long term debtors		404	387	368
Deferred tax assets	10	9.312	7.816	5.549
Total non current assets		257.648	260.690	273.123
Current Assets:				
Inventories	16	4.856	5.340	5.797
Trade accounts receivable	17	163.218	156.303	162.729
Prepayments and other receivables	18	18.887	10.032	11.670
Derivatives	19	1.107	1.677	1.758
Financial assets at fair value through profit and loss	19	1.801	-	-
Cash and cash equivalents	20	3.769	69.524	14.715
Total current assets		193.639	242.877	196.669
TOTAL ASSETS		451.287	503.567	469.792
EQUITY AND LIABILITIES				
Equity attributable to equity holders of the parent company:				
Share capital	21	26.888	26.888	26.888
Share premium	21	19.777	19.777	19.777
Retained Earnings		(966)	4.874	14.389
Legal, tax free and special reserves	22	80.627	80.607	80.621
		126.327	132.146	141.675
Non controlling interests		283	331	199
Total equity		126.610	132.477	141.875
Liabilities :				
Non-current liabilities:				
Long term loans/ borrowings	23	126.674	147.856	2.617
Government Grants	24	1	22	22
Deferred tax liabilities	10	24.768	18.480	20.104
Provision for retirement indemnities	25	12.113	11.633	14.142
Other long term liabilities		-	-	-
Total non-current liabilities		163.556	177.991	36.884
Current liabilities:				
Trade accounts payable	26	84.589	93.751	77.366
Short term loans/ borrowings	23	13.011	16.180	164.090
Long term liabilities payable in the next year	23	28.693	16.322	-
Current tax payable		6.277	11.564	9.524
Derivatives	19	3.424	6.087	8.122
Accrued and other current liabilities	27	25.128	49.195	31.931
Total current liabilities		161.121	193.099	291.033
TOTAL EQUITY AND LIABILITIES		451.287	503.567	469.792

The accompanied notes and appendixes are inseparable part of the financial statements

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF FINANCIAL POSITION OF 30 SEPTEMBER 2013, 31 DECEMBER 2012 AND 31 DECEMBER 2011

	Notes	The Company		
		30-September 2013	31- December 2012 (*)	31- December 2011 (*)
ASSETS				
Non current assets :				
Property, plant and equipment	12	233.178	237.242	238.073
Goodwill	13	-	-	-
Intangible assets	13	216	275	172
Investments in subsidiaries	14	32.889	32.889	32.889
Investments in associates consolidated by the equity method	15	-	-	-
Other long term debtors		400	384	364
Deferred tax assets	10	9.290	7.800	5.487
Total non current assets		275.974	278.590	276.984
Current Assets:				
Inventories	16	4.591	5.084	5.448
Trade accounts receivable	17	162.537	155.503	161.771
Prepayments and other receivables	18	20.283	12.309	29.722
Derivatives	19	1.107	1.677	1.758
Financial assets at fair value through profit and loss	19	1.801	-	-
Cash and cash equivalents	20	3.205	68.944	12.480
Total current assets		193.525	243.517	211.180
TOTAL ASSETS		469.499	522.107	488.164
EQUITY AND LIABILITIES				
Equity attributable to equity holders of the parent company:				
Share capital	21	26.888	26.888	26.888
Share premium	21	19.777	19.777	19.777
Retained Earnings		16.598	22.412	38.817
Legal, tax free and special reserves	22	80.356	80.356	80.356
		143.620	149.433	165.838
Non controlling interests				
Total equity		143.620	149.433	165.838
Liabilities :				
Non-current liabilities:				
Long term loans/ borrowings	23	126.511	147.638	1.624
Government Grants	24	-	-	-
Deferred tax liabilities	10	24.745	18.465	17.893
Provision for retirement indemnities	25	12.046	11.572	13.884
Other long term liabilities		-	-	-
Total non-current liabilities		163.302	177.675	33.402
Current liabilities:				
Trade accounts payable	26	94.804	104.466	84.536
Short term loans/ borrowings	23	10.682	13.817	161.233
Long term liabilities payable in the next year	23	28.693	16.322	-
Current tax payable		5.580	11.051	8.793
Derivatives	19	3.424	6.087	8.122
Accrued and other current liabilities	27	19.395	43.256	26.240
Total current liabilities		162.577	194.999	288.924
TOTAL EQUITY AND LIABILITIES		469.499	522.107	488.164

The accompanied notes and appendixes are inseparable part of the financial statements
(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF CHANGES IN EQUITY 30 SEPTEMBER 2013

The Group						Non controlling Interest	Total Equity
Attributable to equity holders of the parent company							
	Share capital	Share Premium	Legal, Tax-free, and special Reserves	Retained earnings	Total		
Balance, 1 January 2013	26.888	19.777	80.607	3.105	130.378	331	130.708
Adjustement due to retrospective application of revised IAS 19				1.769	1.769		1.769
Balance, 1 January 2013 (*)	26.888	19.777	80.607	4.874	132.146	331	132.477
Total comprehensive income / (loss)			20	(5.839)	(5.819)	24	(5.795)
Attribution of profits to reserves					0		0
Dividends of parent					0		0
Dividends paid to non controlling interests						(73)	(73)
Balance, 30 September 2013	26.888	19.777	80.627	(965)	126.327	283	126.610
The Company							
	Share capital	Share Premium	Legal Tax-free, and special Reserves	Retained earnings	Total Equity		
Balance, 1 January 2013	26.888	19.777	80.356	20.624	147.646		
Adjustement due to retrospective application of revised IAS 19				1.788	1.788		
Balance, 1 January 2013 (*)	26.888	19.777	80.356	22.412	149.433		
Total comprehensive income / (loss)				(5.813)	(5.813)		
Attribution of profits to reserves					0		
Dividends					0		
Balance, 30 September 2013	26.888	19.777	80.356	16.599	143.620		

The accompanied notes and appendixes are inseparable part of the financial statements
(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

STATEMENT OF CHANGES IN EQUITY 30 SEPTEMBER 2012 (*)

The Group							
	Attributable to equity holders of the parent company				Non controlling Interest	Total Equity	
	Share capital	Share Premium	Legal, Tax-free, and special Reserves	Retained earnings	Total		
Balance, 1 January 2012	26.888	19.777	80.621	10.414	137.700	199	137.900
Adjustment due to retrospective application of revised IAS 19				3.975	3.975		3.975
Balance, 1 January 2012 (*)	26.888	19.777	80.621	14.389	141.675	199	141.875
Total comprehensive income / (loss)			(1)	7.704	7.703	160	7.863
Attribution of profits to reserves					0		0
Dividends of parent					0		0
Dividends paid to non controlling interests					0	(17)	(17)
Balance, 30 September 2012	26.888	19.777	80.620	22.093	149.379	342	149.721
The Company							
	Share capital	Share Premium	Legal Tax-free, and special Reserves	Retained earnings	Total Equity		
Balance, 1 January 2012	26.888	19.777	80.356	34.842	161.863		
Adjustment due to retrospective application of revised IAS 19				3.975	3.975		
Balance, 1 January 2012(*)	26.888	19.777	80.356	38.817	165.838		
Total comprehensive income / (loss)				10.756	10.756		
Attribution of profits to reserves					0		
Dividends					0		
Balance, 30 September 2012	26.888	19.777	80.356	49.573	176.595		

The accompanied notes and appendixes are inseparable part of the financial statements

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

CASH FLOW STATEMENT FOR THE PERIOD ENDED SEPTEMBER 2013 AND 2012

	The Group		The Company	
	30- Sep 2013	30- Sep 2012(*)	30- Sep 2013	30- Sep 2012(*)
Cash flows from operating activities:				
Period's profit / (loss) before taxation	(301)	14.295	(673)	17.100
<i>Adjustments for operational activities</i>				
Depreciation	7.069	8.310	6.608	7.240
Depreciation of grants	0	0	0	0
Provision for retirement indemnities (plus actuarial gains/losses)	480	(3.470)	474	(3.270)
Allowance for doubtful accounts receivable	2.406	2.836	2.359	2.836
Other provisions	0	(128)	0	(128)
(Gains)/ Losses due to fixed assets sale	130	97	130	(1)
Impairment expenses of assets / reclassifications	19	189	0	189
Dividends from subsidiaries	(38)	(42)	(33)	(33)
(Gains)/ Losses from group's associates	0	4	0	0
Interest and financial income	(4.162)	(2.177)	(3.844)	(2.166)
Interest and other financial expenses	10.728	10.439	10.577	10.221
Exchange differences due to consolidation of subsidiaries abroad	(19)	0	0	0
Operational profit before changes in working capital variations	16.312	30.352	15.598	31.988
(Increase)/ Decrease in:				
Inventories	484	217	492	198
Short and long term accounts receivable	(18.154)	(61.207)	(17.383)	(63.712)
Increase/ (Decrease) in:				
Short and long term liabilities	(33.194)	42.189	(33.490)	44.933
Interest charges and related expenses paid	(9.557)	(10.439)	(9.406)	(10.221)
Paid taxes	(6.008)	(5.295)	(5.821)	(4.705)
Net Cash from operating activities	(50.117)	(4.183)	(50.010)	(1.519)
Cash flows from investing activities:				
Purchase of tangible and intangible fixed assets	(2.684)	(4.985)	(2.649)	(6.390)
Sale of tangible assets	4	5	0	5
Interest and related income received	1.096	486	778	475
Received dividends from subsidiaries	0	0	33	0
Received dividends from other companies	0	42	0	0
Guarantees paid	0	0	0	0
Grants received	0	0	0	0
Purchase of long and short term investments	(2.000)	0	(2.000)	0
Sales of long and short term investments	0	0	0	0
Net Cash flows used in investing activities	(3.584)	(4.452)	(3.838)	(5.910)
Cash flows from financing activities:				
Issuance of Shares	0	0	0	0
Dividends paid of parent company	0	(25)	0	0
Payment of dividend tax	0	0	0	0
Net variation of short term borrowings	(2.562)	916	(2.562)	916
Net variation of long term debt/ borrowings	(8.104)	246	(8.104)	246
Payment of finance lease liabilities	(1.314)	(1.295)	(1.226)	(892)
Dividends paid to non controlling interests	(73)	0	0	0
Net Cash flows used in financing activities	(12.053)	(158)	(11.892)	270
Net increase/ (decrease) in cash and cash equivalents	(65.755)	(8.794)	(65.740)	(7.159)
Cash and cash equivalents at the beginning of the period	69.524	14.715	68.944	12.480
Cash and cash equivalents at the end of the period	3.769	5.921	3.204	5.321

The accompanied notes and appendixes are inseparable part of the financial statements

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

2. CORPORATE INFORMATION:

The Company “ ATHENS MEDICAL SOCIETE ANONYME” with the distinctive title “ATHENS MEDICAL CENTER S.A.” (hereafter the “Company” or the “Parent Company”) and its subsidiaries (hereafter the “Group”) are involved in the area of health care services with the organization and operation of hospital units. The Company’s and the Group’s head offices are located in the Municipality of Amaroussion Attica in 5- 7 Distomou Street and employ 2.679 and 2.844 employees respectively.

The Company’s shares are publicly traded in the Athens Stock Exchange.

The companies, which were included in the attached interim consolidated financial statements of the Group, together with the related ownership interests are described in table below:

Company’s name	Company’s location country	Activity	% Group’s participation 2013	% Group’s participation 2012	Concolidation method
IATRIKI TECHNIKI S.A.	GREECE	Sale of Medical Tools & Sanitary/Health Equipment	100.00%	100.00%	Total
EREVNA S.A.	GREECE	Diagnostic & Therapeutic Center	51.00%	51.00%	Total
AXONIKI EREVNA S.A.	GREECE	Diagnostic Center	50.50%	50.50%	Total
PHYSIOTHERAPY AND SPORTS INJURY TREATMENT CENTER S.A.	GREECE	Physiotherapy & Sport Injury Restoration/Treatment Services	33.00%	33.00%	Total
HOSPITAL AFFILIATES INTERNATIONAL	GREECE	Organization & Administration of Hospitals and Clinics.	68.89%	68.89%	Total
MEDSANA BMC	ROMANIA	Diagnostic Center	100.00%	100.00%	Total
BIOAXIS SRL (former MEDSANA SRL)	ROMANIA	Diagnostic Center	78.90%	78.90%	Total
EUROSITE HEALTH SERVICES S.A.	GREECE	Establishment & Operation of Hospitals and Clinics, Parking services	100.00%	100.00%	Total
ORTELIA HOLDINGS	CYPRUS	Establishment, Organization & Operation of Hospitals and Clinics	99.99%	99.99%	Total
MATERNITY CLINIC GAIA	GREECE	Maternity and gynaecology clinic	100,00%	100,00%	Total
MEDICAFE S.A.	GREECE	Pastry shop-buffet	55.00%	55.00%	Equity method
INTEROPTICS S.A.	GREECE	Trade & services of publication and electronic information & information systems	27.33%	27.33%	Equity method

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

3a. PREPARATION BASE OF FINANCIAL STATEMENTS:

(a) Basis of Preparation of the Consolidated Financial Statements: These attached interim consolidated and company financial statements for the period ended September 30th 2013 (hereinafter referred to as “interim Financial Statements”) have been prepared according to IAS 34 (Interim Financial Reporting) . These interim financial statements include selected disclosures and not all disclosures required by annual financial statements. Therefore they should be considered in combination with the annual financial statements as of December 31, 2012 which are in accordance with IFRS adopted by the EC.

There are no standards applied in advance of their effective date.

The financial statements have been prepared under the historical cost convention, except for derivative financial instruments and shares traded in the stock market, which are measured at fair value.

The interim financial statements are presented in thousands of euro. It is noted that any deviations are due to roundings.

(b) Statutory Financial Statements: The Company and its domestic (Greek) subsidiaries maintain their accounting books and prepare Financial Statements in accordance to the Greek Company CL 2190/1920 and the applicable tax legislation. The foreign subsidiaries of the Company maintain their accounting records and prepare Financial Statements in accordance to the applicable laws and regulations of the countries in which they operate. For the preparation of the consolidated Financial Statements of the Parent Company, the Financial Statements of the foreign subsidiaries are adjusted in accordance to the provisions of the Greek Company CL 2190/1920. The accompanying consolidated Financial Statements have been based on the above-mentioned statutory consolidated Financial Statements appropriately adjusted and reclassified by certain out-of-book adjustments in order to comply with IFRS.

(c) Approval of Financial Statements: The Board of Directors of Athens Medical S.A. approved the interim financial statements for the period ended in September 30th, 2013, in November 27, 2013.

3b. PRINCIPAL ACCOUNTING POLICIES:

The Accounting policies, estimations and calculation methods adopted for the preparation of these interim Financial Statements are those used for the preparation of the Annual Financial Statements for the year ended December 31,2012 except the retrospective application of standard **IAS 19 “Employee Benefits”** (see below). This retrospective application requires the restatement of previous Financial Statements, which is analyzed in note 25.

New Standards and Interpretations, amendments of valid Standards: The International Accounting Standards Board, as well as the IFRIC, have already issued a number of new accounting standards and interpretations or have amended valid standards, whose application is mandatory for the periods beginning January 1, 2013 onwards (except if mentioned otherwise below). The Group’s and Company’s management’s assessment regarding the effect of these new standards and interpretations is as follows:

A) Standards and Interpretations effective for the periods beginning or after 1 January 2013

IAS 1 (Amendment) “Presentation of Financial Statements” (effective for annual periods beginning on or after July 1, 2012).

The amendment requires entities to separate items presented in other comprehensive income into two groups, based on whether or not they may be recycled to profit or loss in the future (see statement of comprehensive income).

IAS 19 (Amendment) “Employee Benefits” (effective for annual periods beginning on or after January 1, 2013)

This amendment makes significant changes to the recognition and measurement of defined benefit pension expense and termination benefits (eliminates the corridor approach) and to the disclosures for all employee benefits. The key changes relate mainly to recognition of actuarial gains and losses, recognition of past service cost / curtailment, measurement of pension expense, disclosure requirements, treatment of expenses and taxes relating to employee benefit plans and distinction between “short-term” and “other long-term” benefits (Note 25).

IAS 32 (Amendment) “Financial Instruments: Presentation” (effective for annual periods beginning on or after January 1, 2014)

This amendment to the application guidance in IAS 32 clarifies some of the requirements for offsetting financial assets and financial liabilities on the statement of financial position. The Group is in the process of assessing the impact of this amendment on the financial position or performance of the Group.

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

IFRS 7 (Amendment) “Financial Instruments: Disclosures” (effective for annual periods beginning on or after January 1, 2013)

The IASB has published this amendment to include information that will enable users of an entity’s Financial Statements to evaluate the effect or potential effect of netting arrangements, including rights of set-off associated with the entity’s recognized financial assets and recognized financial liabilities, on the entity’s financial position.

IFRS 9 “Financial Instruments” (effective for annual periods beginning on or after January 1, 2015)

IFRS 9 is the first phase of the International Accounting Standards Board’s (“IASB”) project to replace IAS 39 and deals with the classification and measurement of financial assets and financial liabilities. The IASB intends to expand IFRS 9 in subsequent phases in order to add new requirements for impairment and hedge accounting. The Group will quantify the effect in conjunction with the other phases, when the final standard including all phases is issued.

IFRS 13 “Fair Value Measurement” (effective for annual periods beginning on or after January 1, 2013)

IFRS 13 provides new guidance on fair value measurement and disclosure requirements. These requirements do not extend the use of fair value accounting but provide guidance on how it should be applied where its use is already required or permitted by other standards within IFRSs. IFRS 13 provides a precise definition of fair value and a single source of fair value measurement and disclosure requirements for use across IFRSs. Disclosure requirements are enhanced and apply to all assets and liabilities measured at fair value, not just financial ones.

IFRIC 20 “Stripping costs in the production phase of a surface mine” (effective for annual periods beginning on or after January 1, 2013)

This interpretation sets out the accounting for overburden waste removal (stripping) costs in the production phase of a mine. The interpretation does not apply to the Group and the Company

B) Group of standards on consolidation and joint arrangements (effective for annual periods beginning on or after January 1, 2013, unless otherwise stated). The IASB has published five new standards on consolidation and joint arrangements: IFRS 10, IFRS 11, IFRS 12, IAS 27 (amendment) and IAS 28 (amendment). Earlier application is permitted only if the entire “package” of five standards is adopted at the same time. The main provisions are as follows:

IFRS 10 “Consolidated Financial Statements”

The IFRS 10 replaces all of the guidance on control and consolidation in IAS 27 and SIC 12. The new standard changes the definition of control for the purpose of determining which entities should be consolidated. This definition is supported by extensive application guidance that addresses the different ways in which a reporting entity (investor) might control another entity (investee). The revised definition of control focuses on the need to have both power (the current ability to direct the activities that significantly influence returns) and variable returns (can be positive, negative or both) before control is present. The new standard also includes guidance on participating and protective rights, as well as on agency/ principal relationships.

IFRS 11 “Joint Arrangements”

The IFRS 11 provides for a more realistic reflection of joint arrangements by focusing on the rights and obligations of the arrangement, rather than its legal form. The types of joint arrangements are reduced to two: joint operations and joint ventures. Proportional consolidation of joint ventures is no longer allowed. Equity accounting is mandatory for participants in joint ventures. Entities that participate in joint operations will follow accounting much like that for joint assets or joint operations today. The standard also provides guidance for parties that participate in joint arrangements but do not have joint control.

IFRS 12 “Disclosure of Interests in Other Entities”

The IFRS 12 requires entities to disclose information, including significant judgments and assumptions, which enable users of Financial Statements to evaluate the nature, risks and financial effects associated with the entity’s interests in subsidiaries, associates, joint arrangements and unconsolidated structured entities. An entity can provide any or all of the above disclosures without having to apply IFRS 12 in its entirety, or IFRS 10 or 11, or the amended IAS 27 or 28.

IFRS 10, IFRS 11 and IFRS 12 (Amendment) “Consolidated Financial Statements, joint arrangements and disclosure of interests in other entities: Transition guidance

The amendment to the transition requirements in IFRSs 10, 11 and 12 clarifies the transition guidance in IFRS 10 and limits the requirements to provide comparative information for IFRS 12 disclosures only to the period that immediately precedes the first annual period of IFRS 12 application. Comparative disclosures are not required for interests in unconsolidated structured entities.

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

IFRS 10, IFRS 12 and IAS 27 (Amendment) “Investment entities” (effective for annual periods beginning on or after 1 January 2014)

The amendment to IFRS 10 defines an investment entity and introduces an exception from consolidation. Many funds and similar entities that qualify as investment entities will be exempt from consolidating most of their subsidiaries, which will be accounted for at fair value through profit or loss, although controlled. The amendments to IFRS 12 introduce disclosures that an investment entity needs to make.

IAS 27 (Amendment) “Separate Financial Statements”

This standard is issued concurrently with IFRS 10 and together, the two IFRSs supersede IAS 27 “Consolidated and Separate Financial Statements”. The amended IAS 27 prescribes the accounting and disclosure requirements for investment in subsidiaries, joint ventures and associates when an entity prepares separate Financial Statements. At the same time, the IASB relocated to IAS 27 requirements from IAS 28 “Investments in Associates” and IAS 31 “Interests in Joint Ventures” regarding separate Financial Statements.

IAS 28 (Amendment) “Investments in Associates and Joint Ventures”

The amendment IAS 28, replaces IAS 28 “Investments in Associates”. The objective of this standard is to prescribe the accounting for investments in associates and to set out the requirements for the application of the equity method when accounting for investments in associates and joint ventures, following the issue of IFRS 11.

C) Amendments to standards that form part of the IASB’s 2011 annual improvements project. The amendments set out below describe the key changes to IFRSs following the publication in May 2012 of the results of the IASB’s annual improvements project. These amendments are effective for annual periods beginning on or after January 1, 2013 and have not yet been endorsed by the EU:

IAS 1 “Presentation of Financial Statements”

The amendment clarifies the disclosure requirements for comparative information when an entity provides a third balance sheet either (a) as required by IAS 8 “Accounting policies, changes in accounting estimates and errors” or (b) voluntarily

IAS 16 “Property, plant and equipment”

The amendment clarifies that spare parts and servicing equipment are classified as property, plant and equipment rather than inventory when they meet the definition of property, plant and equipment, i.e. when they are used for more than one period.

IAS 32, Financial instruments: presentation.

The amendments would clarify that income tax relating to distributions to holders of an equity instrument and income tax relating to transaction costs of an equity transaction should be accounted for in accordance with IAS 12 Income Taxes. As a result, depending on the circumstances these items of income tax might be recognised in equity or in profit or loss.

IAS 34, Interim financial reporting.

The amendment would clarify that total assets for a particular reportable segment need to be disclosed only when the amounts are regularly provided to the chief operating decision maker and there has been a material change in the total assets for that segment from the amount disclosed in the last annual Financial Statements. Currently there is no reference to the amounts being regularly provided to the chief operating decision maker.

4. RISK MANAGEMENT:

The main activities of the Group are influenced by a variety of financial risks, for example, the risks resulted from changes in foreign currency exchange rates and interest rates. The overall financial risk management program seeks to minimize potential adverse effects in the Group’s financial position as a whole.

The Group’s main financial instruments, except for derivatives and shares, are cash and cash equivalents, bank deposits (sight and time), trade accounts receivable, prepayments and other receivables and accounts payable, bank loans (borrowings). Management periodically evaluates and revises the policies and procedures that relate to management of financial risk, which are described below:

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

a) Market risk

(i) Foreign exchange translation risk (FX translation risk)

The Group holds participations (business operations) in Romania, whose net assets are exposed to FX translation risk. This kind of FX translation risk derives from the exchange rate RON / € and it is not hedged as there is no substantial exposure. Group's management constantly monitors FX translation risks, that might arise and evaluates the need to take relative actions.

(ii) Price risk

The Group is exposed to securities price risk as it has investments in shares classified, in the consolidated Balance Sheet, as financial assets at fair value through the Income Statement. The price risk is considered limited as these investments represent a small part of the Group's assets. The Group's management team constantly monitors related risks and evaluates the need to take relative actions.

(iii) Cash flow and fair value interest rate risk

The Group's interest rate risk arises from borrowings. Borrowings issued at variable rates expose the Group to cash flow interest rate risk. Depending on the levels of net debt, any change in the base interest rates (**EURIBOR**), has a proportionate impact on the Group's results. For diminishing the effect of the above mentioned interest rate risk beginning from year 2008 the Group entered into financial contracts for interest rate risk hedging purposes. These financial instruments are measured at fair value and are recognized as assets or liabilities in the Financial Statements.

The Group's policy is to minimize its exposure to interest rate cash flows risk with regard to financing issued at variable rates, to maintain its borrowings at controlled levels but at the same time make sure of the funding by cooperative banks that satisfy, by all means, the planned growth of the Group.

A detailed report of Company's and Group's loans is found in Note 23.

b) Credit risk

Credit risk arises from credit exposures to customers, including outstanding receivables and conducted transactions. The maximum exposure to credit risk is represented by the carrying amount of each current asset, including derivative financial instruments and shares. The Risk Control Department assesses the credit quality of the customer, taking into account its financial position, past experience and other factors. Trade debtors credit limits are set based on internal ratings in accordance with limits set by management.

The major part of debtors comes from public insurance organizations and private insurance companies, whose credit risk is not considered significant in terms of the Group's assets and liabilities except for extraordinary events. Regarding the rest of the debtors represented by sales to individuals, risk is diversified due to the large number of debtors (See note 17).

Regarding prepayments and other receivables, credit risk is considered of no significance.

With respect to shares owned and derivative financial instruments, the Group monitors its positions, while especially regarding the derivative financial instruments monitors also the credit ratings of counter parties (See note 19) and the level of contracts it enters into with any counter party.

Additionally, regarding the risks on deposits and equivalent products, the Group has transactions only with recognized financial institutions, with high credit ratings.

c) Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash and cash equivalents, the availability of funding through an adequate amount of committed credit facilities. Furthermore, the Group estimates and controls its cash flows and it has entered into factoring transactions, aiming to support its working capital (See note 23 and note 17).

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

In the financial liabilities of the Group and the Company the derivatives are included, in which the Group monitors its positions, and the level of contracts it enters into, with any counter party. A detailed report is found in Note 19.

d) Capital management policies and procedures

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

e) Fair value estimation

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques based on market conditions existing at each balance sheet date.

The nominal value less estimated credit adjustments of trade receivables is assumed to approximate their fair values.

Since January 1 2009, Group applies the amendment of IFRS 7, which requires the disclosure of financial assets measured at fair value according to a hierarchy of 3 levels.

- Published purchase prices (not revised or adjusted) for financial assets that are traded in active capital markets (**level 1**)
- Valuation techniques based directly on published purchase prices or computed indirectly from published purchase prices of similar instruments (**level 2**)
- Valuation techniques which are not based on available information from current transactions in active capital markets (**level 3**)

In the table below financial assets and liabilities, which are measured at fair value at 30th September 2013 and 31st December 2012, are shown:

Group 2012	Level 1	Level 2	Level 3	Total
Financial assets				
(Interest rate swaps)		1.677		1.677
Financial liabilities				
(Interest rate swaps)		6.087		6.087
Group 30.9.2013	Level 1	Level 2	Level 3	Total
Financial assets				
(Interest rate swaps)		1.107		1.107
Financial assets at fair value through profit and loss (shares traded in the stock market as well as traded warrants)	1.801			1.801
Financial liabilities				
(Interest rate swaps)		3.424		3.424
Company 2012	Level 1	Level 2	Level 3	Total
Financial assets				
(Interest rate swaps)		1.677		1.677
Financial liabilities				
(Interest rate swaps)		6.087		6.087

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Company 30.9.2013

	Level 1	Level 2	Level 3	Total
Financial assets				
(Interest rate swaps)		1.107		1.107
Financial assets at fair value through profit and loss (shares traded in the stock market as well as traded warrants)	1.801			1.801
Financial liabilities				
(Interest rate swaps)		3.424		3.424

The derivatives' and shares' fair value is based on market to market assessment. For derivatives (Interest rate swaps), fair values are confirmed from financial institutions with which the group has entered relevant contracts (See Note 19).

During the period no reclass took place among levels 1, 2, 3 relevant to fair value measurement.

The fair value of financial assets, which are not traded in active capital markets, (for example derivatives over the counter) is measured by using valuation techniques, based mainly on available information about transactions that take place in active markets while using the least possible entity's estimations. These financial instruments are included in level 2.

5. PAYROLL COST:

The Payroll cost that is included in the accompanying financial statements is analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>30/9/2012</u> (*)	<u>30/9/2013</u>	<u>30/9/2012</u> (*)
Wages and Salaries	41.799	46.389	40.575	44.369
Social security costs	10.614	11.488	10.281	10.923
Compensations and Provision for retirement indemnities	1.076	826	1.070	814
Management fees and other staff expenses	2.252	2.355	2.167	2.246
Total payroll	55.741	61.058	54.093	58.352
Less: amounts charged to cost of sales	(44.919)	(49.542)	(44.394)	(48.144)
Administrative and distribution cost (Note 7)	10.821	11.516	9.699	10.208

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

6. DEPRECIATION AND AMORTISATION:

Depreciation and amortization accounted in the accompanying financial statements is analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>30/9/2012</u>	<u>30/9/2013</u>	<u>30/9/2012</u>
Depreciation of property plant and equipment (Note 12)	6.939	8.202	6.539	7.169
Amortization of intangible assets (Note 13)	130	108	69	71
	7.069	8.310	6.608	7.240
Less: depreciation and amortization charged to cost of sales	(6.352)	(7.588)	(6.099)	(6.736)
Administrative and distribution cost (Note 7)	717	722	509	504

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

7. ADMINISTRATIVE EXPENSES AND DISTRIBUTION COSTS:

The administrative expenses and distribution costs that are presented in the accompanying financial statements are analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>30/9/2012(*)</u>	<u>30/9/2013</u>	<u>30/9/2012(*)</u>
Payroll cost (Note 5)	10.821	11.516	9.699	10.208
Third party fees	2.937	5.400	2.623	5.009
Depreciation and amortization (Note 6)	717	722	509	504
Third party services	1.443	1.541	1.282	1.345
Provisions	2.406	2.836	2.359	2.836
Other expenses	5.737	5.346	5.044	4.590
Total	24.062	27.360	21.515	24.493

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

8. OTHER INCOME / (EXPENSES):

The other income / (expenses) that are presented in the accompanying financial statements are analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>30/9/2012(*)</u>	<u>30/9/2013</u>	<u>30/9/2012(*)</u>
Income from rentals/other services	1.013	935	1.111	1.064
Government Grants, special tax returns	10	18	8	18
Other income	657	1.277	676	1.275
Profit / (loss) on disposals of fixed assets	(130)	(97)	(130)	1
Income from reversal of provisions	-	3.566	-	3.398
Income from prior years	903	180	147	178
Total	2.453	5.880	1.812	5.934

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

9. FINANCIAL INCOME/(COSTS):

The financial income/ (costs) that are presented in the accompanying financial statements are analyzed as follows:

The Group	<u>30/9/2013</u>	<u>30/9/2012</u>
Interest on non-current loans/borrowings	(6.014)	0
Interest on current loans/borrowings & relevant expenses	(803)	(7.776)
Financial expenses from derivatives	(2.262)	(2.270)
Factoring commissions	(446)	(287)
Finance lease interest	(32)	(105)
Securities valuation at fair value (shares)	(601)	0
Derivative valuation at fair value	(570)	0
Losses from exchange differences	0	0
Total financial costs	(10.728)	(10.438)
Gains / (losses) from associates	0	(4)
Dividends from investments in companies	38	42
Interest on deposits and relevant income	546	48
Income from derivatives	549	439
Derivative valuation at fair value	2.663	1.691
Warrants valuation at fair value	403	0
Gains from exchange differences	0	0
Total financial income	4.200	2.215
Financial income/(costs)	(6.528)	(8.223)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The Company

	<u>30/9/2013</u>	<u>30/9/2012</u>
Interest on non-current loans/borrowings	(6.014)	0
Interest on current loans/borrowings & relevant expenses	(665)	(7.597)
Financial expenses from derivatives	(2.262)	(2.270)
Factoring commissions	(446)	(287)
Finance lease interest	(19)	(66)
Securities valuation at fair value (shares)	(601)	0
Derivative valuation at fair value	(570)	0
Total financial costs	(10.577)	(10.221)
Interest on deposits and relevant expenses	229	36
Income from derivatives	549	439
Derivative valuation at fair value	2.663	1.691
Warrants valuation at fair value	403	0
Dividends from investments in companies	33	33
Total financial income	3.877	2.199
Financial income/(costs)	(6.700)	(8.022)

10. INCOME TAXES:

According to the tax legislation, the tax rate applicable in companies for the year of 2013 is 26%. (20 % the 31st of December 2012).

Income taxes for interim financial statements are calculated based on the valid income tax rate.

The income taxes presented in the accompanying financial statements is analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>30/9/2012</u> (*)	<u>30/9/2013</u>	<u>30/9/2012</u> (*)
Current income taxes:				
Current income tax charge (and other taxes not included in the operating cost)	721	3.632	350	3.509
Deferred income taxes	4.618	1.556	4.615	1.606
Total income taxes	5.339	5.188	4.965	5.115

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

The effect of the transition from 20% to 26% tax rate, included in the amount of deferred tax for period 1/1-30/9/2013 in both group and company level amounts to €3.2mil. (see six month report at 30/6/2013).

Greek tax laws and related regulations are subject to interpretations by the tax authorities. Tax returns are filed annually but the profits or losses declared for tax purposes remain provisional until such time, as the tax authorities examine the returns and the records of the taxpayer and a final assessment is issued. Tax losses, to the extent accepted by the tax authorities, can be used to offset profits of the five fiscal years following the fiscal year to which they relate.

In a future tax audit of the related unaudited years, additional taxes and penalties may be assessed to the Company and to its subsidiaries. The Group regards that the outcome of the tax audits and the amount of the possible added taxes and fines, is possible to be estimated and thus, a relevant provision has been made in the consolidated Financial Statements related to this subject, amounted to € 1.010 of which € 950 refer to the Parent Company. Parent Company has not been audited by tax authorities for fiscal years 2009 and 2010.

For year 2011 and 2012 an audit has been carried out in terms of providing annual tax compliance certificate, according to the provisions of paragraph 5 of article 82 of CL 2238/94 as well as relevant explanatory circular POL 1159/2011, for the Parent Company and its subsidiaries with residence in Greece. The years that have been audited are considered to be finally assessed after 18 months, starting from the above mentioned certificate's issuance date.

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Regarding its subsidiaries, the tax authorities have not audited their books and their elements for the years mentioned in table below:

Company's name	Company's location country	Activity	Participation (%)	Tax unaudited years
IATRIKI TECHNIKI S.A.	GREECE	Sale of Medical Tools & Sanitary/Health Equipment	100.00%	2009-2010
EREVNA S.A.	GREECE	Diagnostic & Therapeutic Center	51.00%	2007-2012
AXONIKI EREVNA S.A.	GREECE	Diagnostic Center	50.50%	2007-2012
PHYSIOTHERAPY AND SPORTS INJURY TREATMENT CENTER S.A.	GREECE	Physiotherapy & Sport Injury Restoration/Treatment Services	33.00%	2010
HOSPITAL AFFILIATES INTERNATIONAL S.A.	GREECE	Organization & Administration of Hospitals and Clinics	68.89%	2007-2010 & 2012
MEDSANA B.M.C.	ROMANIA	Diagnostic Center	100.00%	1997-2012
BIOAXIS S.R.L. (ex MEDSANA S.R.L.)	ROMANIA	Diagnostic Center	78.90%	1997-2012
EUROSITE HEALTH SERVICES S.A.	GREECE	Establishment & Operation of Hospitals and Clinics and parking services	100.00%	2010
ORTELIA HOLDINGS	CYPRUS	Establishment, Organization & Operation of Hospitals and Clinics	99.99%	1998-2012
MEDICAFE S.A.	GREECE	Pastry shop-buffet	55%	2007-2010
MATERNITY CLINIC GAIA S.A.	GREECE	Maternity and gynaecology clinic	100.00%	2009-2010
INTEROPTICS S.A.	GREECE	Trade & services of publication and electronic information & information systems	27.33%	2010

The deferred income taxes related to the temporary differences between the book values and the tax bases of assets and liabilities are calculated using the applicable statutory income tax rate (26%).

	<u>The Group</u>	<u>The Company</u>
Opening balance, January 1 st 2012	(13.561)	(11.412)
Adjustement due to retrospective application of revised IAS 19	(994)	(994)
Opening balance, January 1st 2012 (*)	(14.555)	(12.406)
Charged directly to equity	415	410
Charged to the statement of income	3.476	1.332
Closing balance, December, 31st 2012	(10.664)	(10.664)

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

	<u>The Group</u>	<u>The Company</u>
Opening balance, January 1 st 2013	(10.222)	(10.217)
Adjustement due to retrospective application of revised IAS 19	(442)	(447)
Opening balance, January 1st 2013 (*)	(10.664)	(10.664)
Charged directly to equity	(174)	(175)
Charged to the statement of income	(4.618)	(4.615)
Closing balance, 30th September 2013	(15.456)	(15.455)

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	<u>The Group</u>		<u>The Company</u>	
	<u>30th</u> <u>September</u> <u>2013</u>	<u>31st</u> <u>December</u> <u>2012</u>	<u>30th</u> <u>September</u> <u>2013</u>	<u>31st</u> <u>December</u> <u>2012</u>
Deferred income tax Liabilities:				
- Property plant and equipment	(23.743)	(18.053)	(23.737)	(18.041)
- Leases	(1.524)	(1.164)	(1.508)	(1.160)
- Other	499	737	499	737
	(24.768)	(18.480)	(24.745)	(18.465)
Deferred income tax Assets:				
- Accounts receivable	5.908	5.274	5.908	5.274
- Tax losses	0	0	0	0
- Deferred expenses	300	261	295	258
- Provision for retirement indemnities	3.149	2.327	3.132	2.314
- Other	(46)	(46)	(46)	(46)
	9.312	7.816	9.290	7.800
Net deferred income tax liabilities	(15.456)	(10.664)	(15.455)	(10.664)

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

The effect of the deferred taxes in debits/(credits) of the income statement and the statement of comprehensive income is the following:

	<u>The Group</u>		<u>The Company</u>	
	<u>30th</u> <u>September</u> <u>2013</u>	<u>31st</u> <u>December</u> <u>2012</u>	<u>30th</u> <u>September</u> <u>2013</u>	<u>31st</u> <u>December</u> <u>2012</u>
Deferred income tax Liabilities:				
- Property plant and equipment	(5.690)	2.019	(5.695)	(86)
- Leases	(360)	230	(347)	141
- Other	(238)	(626)	(237)	(626)
	(6.288)	1.624	(6.280)	(571)
Deferred income tax Assets:				
- Accounts receivable	634	2.802	634	2.802
- Tax losses	0	(37)	0	0
- Deferred expenses	39	(26)	38	(26)
- Provision for retirement indemnities (*)	823	(471)	818	(462)
- Other	0	0	0	0
	1.496	2.267	1.490	2.313
Debit / (Credit) of deferred income tax	(4.792)	3.891	(4.790)	1.742

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

Group has not formed deferred tax asset, for accumulated tax losses of companies included in the consolidation.

11. EARNINGS PER SHARE:

The calculation of basic earnings per share in the 30th of September 2013 and 2012 is the following:

	<u>The Group</u>		<u>The Company</u>	
	<u>30th</u> <u>September</u> <u>2013</u>	<u>30th</u> <u>September</u> <u>2012 (*)</u>	<u>30th</u> <u>September</u> <u>2013</u>	<u>30th</u> <u>September</u> <u>2012(*)</u>
Net profit / (loss) attributable to equity holders of the parent	(5.665)	8.948	(5.638)	11.985
Weighted average number of shares outstanding	86.735.980	86.735.980	86.735.980	86.735.980
Basic earnings / (losses) per share				
Net profit / (loss) per share attributable to equity holders of the parent	(0,07)	0,10	(0,07)	0,14

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The diluted earnings per share are not presented, as they do not differ from basic earnings per share mentioned above.

Profit before taxes, financing and investing activity and profit before taxes, financing, investing activity and depreciation of Group and Company, for the periods 1/1-30/9/2013 and 1/1-30/9/2012 are, for purposes of decision 34/24.1.2008 of Capital Market's Board of Directors Commission as following :

	The Group		The Company	
	30th September 2013	30th September 2012(*)	30th September 2013	30th September 2012(*)
Profit before taxes, financing and investing activity	6.357	22.616	6.157	25.122
Profit before taxes, financing, investing activity and depreciation	13.426	30.926	12.765	32.362

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

12. PROPERTY PLANT AND EQUIPMENT:

Property, plant and equipment is analyzed as follows:

<i>Movement for year 2012 – Group</i>							
	Land	Buildings and installations	Machinery and equipment	Transportation equipment	Furniture and fixtures	Construction / Purchases in Progress	Total
<u>Cost or measurement</u>							
Balance 01.01.2012	67.837	188.778	78.203	2.342	32.257	9.678	379.095
Exchange Differences	0	0	(40)	(5)	(4)	0	(49)
Additions	0	454	2.047	8	933	3.959	7.402
Sales/Deletions	0	0	(2.231)	(59)	(158)	(6)	(2.454)
Adjustments	0	0	0	0	0	0	0
Impairment	(9.751)	(78)	0	0	0	0	(9.829)
Transfers from fixed assets under constructions	0	5.609	0	0	0	(5.609)	0
Transitions and reclassifications	0	0	0	0	0	0	0
Balance 31.12.2012	58.086	194.763	77.979	2.286	33.028	8.021	374.165
<u>Depreciation</u>							
Balance 01.01.2012	0	(29.489)	(54.623)	(1.854)	(26.601)	0	(112.567)
Exchange Differences	0	5	32	4	2	0	43
Additions	0	(4.220)	(4.928)	(131)	(1.443)	0	(10.722)
Sales/Deletions	0	0	736	58	79	0	873
Adjustments	0	0	0	0	0	0	0
Transitions and reclassifications	0	(4)	11	5	(5)	0	6
Year total	0	(4.219)	(4.149)	(64)	(1.367)	0	(9.800)
Balance 31.12.2012	0	(33.707)	(58.772)	(1.918)	(27.967)	0	(122.366)
Net Book Value 31.12.2012	58.086	161.056	19.207	368	5.061	8.021	251.798

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Movement for a' nine months of 2013 – Group

	Land	Buildings and installations	Machinery and equipment	Transportation equipment	Furniture and fixtures	Construction / Purchases in Progress	Total
<u>Cost or measurement</u>							
Balance 01.01.2013	58.086	194.763	77.979	2.286	33.028	8.021	374.165
Exchange Differences	19	0	0	0	0	0	19
Additions	0	422	534	3	505	1.205	2.668
Sales/Deletions	0	(34)	(853)	0	0	0	(888)
Impairment	0	0	0	0	0	0	0
Transfers from fixed assets under constructions	0	0	5	0	0	(14)	(9)
Transitions and reclassifications	(19)	0	0	0	0	0	(19)
Balance 30.9.2013	58.086	195.150	77.666	2.289	33.533	9.211	375.936
Depreciation							
Balance 01.01.2013	0	(33.707)	(58.772)	(1.918)	(27.967)	0	(122.366)
Exchange Differences	0	0	0	0	0	0	0
Additions	0	(2.932)	(3.015)	(70)	(922)	0	(6.939)
Sales/Deletions	0	1	720	0	0	0	721
Transitions and reclassifications	0	0	0	0	0	0	0
Period total	0	(2.931)	(2.295)	(70)	(922)	0	(6.218)
Balance 30.9.2013	0	(36.638)	(61.068)	(1.988)	(28.889)	0	(128.584)
Net Book Value 30.9.2013	58.086	158.512	16.598	301	4.644	9.211	247.352

In the previous year 2012 and for granting securities for the purpose of renegotiating its long term borrowings, Group due to impairment test on its land and buildings, recognised a relevant expense amounted to 9,8mil euro.

Movement for year 2012 – Company

	Land	Buildings and installations	Machinery and equipment	Transportation equipment	Furniture and fixtures	Construction / Purchases in Progress	Total
<u>Cost or measurement</u>							
Balance 01.01.2012	51.308	184.254	69.749	1.873	30.028	5.292	342.505
Additions	0	454	2.375	8	1.814	3.951	8.602
Sales/ Deletions	0	0	(7)	(12)	(12)	0	(31)
Adjustments	0	0	0	0	0	0	0
Transfers from fixed assets under constructions	0	5.609	0	0	0	(5.609)	0
Transitions and reclassifications	0	0	0	0	0	0	0
Balance 31.12.2012	51.308	190.317	72.117	1.869	31.830	3.635	351.076
Depreciation							
Balance 01.01.2012	0	(26.882)	(50.568)	(1.451)	(25.531)	0	(104.432)
Additions	0	(3.748)	(4.280)	(80)	(1.325)	0	(9.433)
Sales/ Deletions	0	0	5	11	10	0	26
Adjustments	0	0	0	0	0	0	0
Transitions and reclassifications	0	(5)	12	5	(6)	0	6
Year Total	0	(3.753)	(4.264)	(64)	(1.321)	0	(9.402)
Balance 31.12.2012	0	(30.635)	(54.832)	(1.515)	(26.852)	0	(113.833)
Net Book Value 31.12.2012	51.308	159.682	17.285	354	4.978	3.635	237.242

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Movement for a' nine months of 2013- Company

	Land	Buildings and installations	Machinery and equipment	Transportation equipment	Furniture and fixtures	Construction / Purchases in Progress	Total
Cost or measurement							
Balance 01.01.2013	51.308	190.317	72.117	1.869	31.830	3.635	351.076
Additions	0	422	523	3	500	1.191	2.639
Sales / Deletions	0	(34)	(850)	0	0	0	(884)
Transitions and reclassifications	0	0	0	0	0	0	0
Transfers from fixed assets under constructions	0	0	0	0	0	0	0
Balance 30.9.2013	51.308	190.704	71.790	1.872	32.331	4.827	352.831
Depreciation							
Balance 01.01.2013	0	(30.635)	(54.832)	(1.515)	(26.852)	0	(113.833)
Additions	0	(2.857)	(2.716)	(58)	(908)	0	(6.540)
Sales/Deletions	0	1	720	0	0	0	721
Transitions and reclassifications	0	0	0	0	0	0	0
Period total	0	(2.856)	(1.996)	(58)	(908)	0	(5.819)
Balance 30.9.2013	0	(33.491)	(56.829)	(1.573)	(27.760)	0	(119.652)
Net Book Value 30.9.2013	51.308	157.213	14.961	299	4.571	4.827	233.178

There is mortgage attachment amounted to 196,8 mil, which is registered on parent company's land and buildings. No item of machinery equipment has been pledged as security for liabilities.

13. INTANGIBLE ASSETS

The Group

	Goodwill	Rights/Licenses	Other (Software)	Total
Cost				
Balance 01.01.2012	0	66	1.498	1.564
Exchange Differences	0	0	(4)	(4)
Additions	0	0	66	66
Sales/Deletions	0	0	(11)	(11)
Adjustments	0	0	0	0
Transitions	0	0	0	0
Balance 31.12.2012	0	66	1.549	1.615
Accumulated amortization				
Balance 01.01.2012	0	0	(1.237)	(1.237)
Exchange Differences	0	0	1	1
Additions	0	0	(176)	(176)
Adjustments	0	0	0	0
Sales / Deletions	0	0	9	9
Transitions / Reclassifications	0	0	128	128
Balance 31.12.2012	0	0	(1.275)	(1.275)
Net Book Value 31.12.2012	0	66	274	340

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	Goodwill	Rights / Licenses	Other (Software)	Total
Cost				
Balance 01.01.2013	0	66	1.549	1.615
Exchange Differences	0	0	0	0
Additions	0	0	13	13
Sales / Deletions	0	0	0	0
Transitions	0	0	9	9
Balance 30.9.2013	0	66	1.571	1.636
Accumulated amortization				
Balance 01.01.2013	0	0	(1.275)	(1.275)
Exchange Differences	0	0	0	0
Additions	0	0	(130)	(130)
Sales / Deletions	0	0	0	0
Balance 30.9.2013	0	0	(1.404)	(1.404)
Net Book Value 30.9.2013	0	66	167	232

The Company

	Rights / Licenses	Other (Software)	Total
Cost			
Balance 01.01.2012	66	1.207	1.273
Additions	0	69	69
Adjustments	0	0	0
Balance 31.12.2012	66	1.276	1.342
Accumulated amortization			
Balance 01.01.2012	0	(1.102)	(1.102)
Additions	0	(94)	(94)
Adjustments	0	0	0
Transitions	0	128	128
Balance 31.12.2012	0	(1.068)	(1.068)
Net Book Value 31.12.2012	66	209	275

	Rights / Licenses	Other (Software)	Total
Cost			
Balance 01.01.2013	66	1.276	1.342
Additions	0	10	10
Sales/Deletions	0	0	0
Balance 30.9.2013	66	1.286	1.352
Accumulated amortization			
Balance 01.01.2013	0	(1.068)	(1.068)
Additions	0	(69)	(69)
Sales/Deletions	0	0	0
Balance 30.9.2013	0	(1.136)	(1.136)
Net Book Value 30.9.2013	66	150	216

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

14. INVESTMENTS OF PARENT COMPANY IN SUBSIDIARIES

The investments of the Company in subsidiaries at the 30th September 2013 are analyzed as follows:

	Participation percentage	Acquisition cost in 30/9/2013	Acquisition cost in 31/12/2012
Iatriki Techniki S.A.	100,00%	25.421	25.421
Physiotherapy center S.A.	33,00%	19	19
Axoniki Erevna S.A.	50,50%	545	545
Erevna S.A	51,00%	503	503
Hospital Affiliates International S.A.	68,89%	91	91
Eurosite S.A	100,00%	8.335	8.335
Ortelia Holdings	99,99%	1.039	1.039
Medsana Buch	100,00%	33	33
BIOAXIS SRL (former Medsana Srl)	78,90%	517	517
Athens Paediatrics Center	58,30%	169	169
Maternity clinic Gaia S.A.	100,00%	23.540	23.540
		60.212	60.212
Impairment loss		(27.323)	(27.323)
Balance		32.889	32.889

The above-mentioned subsidiaries are consolidated, except from Athens Pediatrics Center SA, which is under liquidation procedure and its acquisition cost is totally deleted in the Company's retained earnings. The operation of this company was interrupted before the transition date, the assets and liabilities of its balance sheets are of minor significance and the liquidation procedure does not entail significant costs for the Company. Until the reporting date of the accompanying Financial Statements no final judicial decision has been issued for its dissolution and its final deletion from the S.A. register.

The acquisition cost in Ortelia Holdings SA and in BIOAXIS SRL (former Medsana Srl) has been completely deleted in the stand alone Financial Statements of the Company, according to the provisions of IAS 27 and 38. These companies, do not present any operation and their accounting value is greater of their recoverable amount. At the transition date in IFRS, an impairment test took place in the above mentioned investments, during which, it was attributed in Company's cash generating units. The recoverable amount, which in this case was the value of use, was lower than the carrying amount and the impairment loss arose and amounted to € 1,805, was charged against the retained earnings of 1st of January 2004.

In 2012 subsidiaries Hospital Affiliates International and Ortelia Holdings entered liquidation procedure. It is noted that the companies had not any revenue since, while their assets are only current and of no significance compared to the Group's ones. The companies Axoniki Erevna S.A. and Erevna S.A remain in liquidation procedure up to date.

Movement of Impairment is as follows:

	30/9/2013	31/12/2012
Impairment at the beginning of the period	(27.323)	(9.708)
Participation impairment in Gaia S.A.	0	(17.615)
Impairment at the end of the period	(27.323)	(27.323)

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Impairment is analyzed as follows:

	Participation percentage	Impairment at 30/9/2013	Impairment at 31/12/2012
Iatriki Techniki S.A.	100,00%	1.978	1.978
Axoniki Erevna S.A.	50,50%	39	39
Erevna S.A	51,00%	28	28
Hospital Affiliates International S.A.	68,89%	13	13
Ortelia Holdings	99,99%	1.039	1.039
BIOAXIS SRL (former Medsana Srl)	78,90%	517	517
Athens Paediatrics Center	58,30%	169	169
Maternity clinic Gaia S.A.	100,00%	23.540	23.540
Total		(27.323)	(27.323)

The dividends of subsidiaries for year 2012, are the following:

	Income from dividends
Physiotherapy center S.A.	33
TOTAL	33

The dividends of subsidiaries for a' nine months of 2013, are the following:

	Income from dividends
Physiotherapy center S.A.	33
TOTAL	33

There are no dividends from subsidiaries that have been sold during previous year 2012, nor during the a' nine months of 2013.

15. INVESTMENTS IN ASSOCIATES CONSOLIDATED BY THE EQUITY METHOD

These concern Company's investments in the capital share of the following companies in a percentage between 20% and 50% and in which no important influence is exercised.

The Company

	Participation percentage	Acquisition cost in 30/9/2013	Acquisition cost in 31/12/2012
Medisoft S.A.	45,00%	132	132
Interoptics S.A.(ex-In Health S.A.)	27,33%	205	205
Aggiologiki Dierevnisi Ltd	20,00%	2	2
Herodikos Ltd	20,00%	19	19
		358	358
Impairment loss		(358)	(358)
Net carrying amount		0	0

The carrying amount of the above companies is deleted in the Company's Equity at a time prior to the transition date and the same classification is preserved since the 1st January 2004.

It is noted that company In Health S.A. was merged through absorption from company Interoptics S.A. at 15 March 2005 and as a result Group obtains a percentage of 27.33% on the capital of Interoptics S.A. instead of 30.37% that was obtained on the capital of the absorbed company In Health S.A.

The Group

	30/9/2013	31/12/2012
Percentage in equity at the beginning of the year	348	352
Gain from associates – Interoptics S.A., Medicafe SA	38	38
Recognized income from dividends of company Medicafe SA (Note 9)	(38)	(42)
Total	348	348

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The total amount of gain from associates of € 38 (€41 minus € 3) has been included in the financial income (Note 9).

The dividends of associates for year 2012 are the following:

	Income from dividends
Medicafe S.A.	42

The dividends of associates for a' nine months of 2013 are the following:

	Income from dividends
Medicafe S.A.	38

There are no dividends from associates that have been sold during previous year 2012, nor during the a' nine months of 2013.

16. INVENTORIES:

The inventories are analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Merchandise	71	37	0	0
Raw materials and consumable materials	4.785	5.303	4.591	5.084
Finished and semi-finished products	0	0	0	0
	4.856	5.340	4.591	5.084

No item of inventories of Group and Company has been pledged as security for liabilities.

17. TRADE ACCOUNTS RECEIVABLE:

The trade accounts receivable are analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Trade debtors – open balances	171.521	165.161	170.891	164.537
Checks receivable (postdated) & bills receivable	19.191	20.860	19.124	20.790
Doubtfull debtors	1.633	1.716	1.602	1.610
Less: Provision for impairment (trade debtors)	(28.814)	(31.121)	(28.767)	(31.121)
Less: Provision for impairment (trade accounts receivable)	(313)	(313)	(313)	(313)
	163.218	156.303	162.537	155.503

These short term financial assets' fair value is not fixed independently because it is considered that book value approaches their fair value.

The major part of trade debtors comes from public insurance organizations and private insurance companies, whose credit risk is not considered significant in terms of Groups's assets and liabilities, except extraordinary events. Regarding the rest of debtors, represented by sale to individuals, risk is diversified due to the great number of debtors.

The group impairs the value of trade receivables when there is evidence or indications that the collection of each receivable in whole or up to a percentage is not feasible. The Management of the Group proceeds to temporary revaluation of the formulated provision for doubtful debts in relation with the credit policy and data from the Group's Law Department, which arises from processing past data and recent developments of each case.

For all Group receivables, indications for their probable impairment have been assessed.

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

We note that according to Law 4132 (GG 59A – 7/3/2012) and the Ministerial Decision no. 18579 of 19/02/2013 (GG 427B – 25/2/2013) the percentage of discount for the payment of receivables from Public Funds included in EOPYY prior to 31/12/2011, has been set at 8%. For this reason within previous year 2012 the Group has formed a provision for credit notes amounting to € 20.298. In period 1/1-30/9/2013 credit notes have been issued after the clearance of part of relevant debtors, amounted to € 4.713 with equal decrease of the relevant provision that had been formed in previous year 2012.

The adequacy of the above mentioned provision of €20.298 and regarding possible new discounts for current year 2013, from EOPYY, will be assessed by company's management at current year's end,

The company after the impairment amounted to € 2.405 that had been formed in year 2010 for debtors against the companies «Commercial Value S.A.» and «Aspis Pronoia S.A.» formed additional impairment for these debtors by € 1.109 (included in the amount of € 2.359 in the table below), as it accepted further decrease of these debtors after final clearance. The total provision for the above mentioned debtors at 30/9/2013 amounts to € 3.514.

In period 1/1-30/9/2013 an additional impairment has been formed, for doubtful debtors, of euro 2.406 (see note 7). In addition, some of the non impaired receivables are in delay.

Specifically the impairment account has as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Opening balance	31.434	12.180	31.434	12.180
Provision for impairment of public insurance funds receivables	0	20.298	0	20.298
Debtors impairment that charged the results (see note 7)	2.406	3.154	2.359	3.154
Decrease of provision due to the issuance of credit notes (see above)	(4.713)	0	(4.713)	0
Deletion of receivables with equal deletion of accumulated provision of debtors impairment	0	(4.198)	0	(4.198)
Closing balance	29.127	31.434	29.080	31.434

It is noted that the company in terms of the new common bond loan (see note 23) and granting securing in favour of borrowing banks, has transferred trade debtors amounted to €51,05mil., on September 30th 2013.

The company did not derecognise the above mentioned trade debtors from its Financial Statements and the counterparty (the receiver of the transfer) is obliged to return to the Company the amount received from these trade debtors. The counterparty is entitled to retain the amount received from the trade debtors only when amounts due, that are owed to the banks, exist.

It is noted that the company's obligations to lending banks, that must be paid in the following 12 months starting from reporting date (30/9/2013), amount to € 28,7 mil. (long term liabilities payable in the next year), as well as almost € 7,5 mil., amount that is estimated to be the financial expense of bond loan for the above mentioned period.

Group's trade accounts receivable mainly consist of receivables in euro.

18. PREPAYMENTS AND OTHER RECEIVABLES:

The prepayments and other receivables are analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Advances to third parties	167	151	128	112
Other accounts receivable	9.605	8.251	8.107	7.803
Short-term receivables from associates	0	0	5.440	5.705
Impairment of receivables from associates (Ortelia)	0	0	(1.729)	(1.729)
Prepaid expenses, accrued income and other debtors	9.115	1.630	8.337	418
	18.887	10.032	20.283	12.309

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

In other accounts receivable in 30th September 2013, retained and advanced income taxes are included, amounted to € 5.063 for Group (€2.920 at 31st December 2012) and € 4.712 (€644 at 31st December 2012) for the Company.

19a. DERIVATIVES:

	<u>The Group</u>		<u>The Company</u>	
	<u>Assets</u>		<u>Assets</u>	
	<u>Fair value</u>		<u>Fair value</u>	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Interest rate Derivatives. (Swaps) (Contracts' nominal value 19.000.000 euro)- (21.000.000 euro at 31/12/2012)	1.107	1.677	1.107	1.677
	1.107	1.677	1.107	1.677

	<u>The Group</u>		<u>The Company</u>	
	<u>Total Equity and liabilities</u>		<u>Total Equity and liabilities</u>	
	<u>Fair value</u>		<u>Fair value</u>	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Interest rate Derivatives. (Swaps) (Contracts' nominal value 57.000.000 euro)- (105.000.000 euro at 31/12/2012)	3.424	6.087	3.424	6.087
	3.424	6.087	3.424	6.087

The derivatives' fair value is based on market to market assessment. For all swap contracts, fair values are confirmed from financial institutions with which the group has entered relevant contracts.

The financial income/ expenses from derivatives for the first nine months of 2013 is mentioned in detail in note 9.

SWAPS

Swaps in 30th September 2013 and 31st December 2012 were as following:

	Bank	Maturity	Interest Swaps	
			Collections (based)	Payments (based)
	National Bank of Greece	7/2015	Euribor 6month	fixed
	Alpha Bank	7/2015	Euribor 6month	Libor 6month
	Unicredit	7/2015	fixed	Euribor 6month

19b. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS:

	<u>The Group</u>		<u>The Company</u>	
	<u>Assets</u>		<u>Assets</u>	
	<u>Fair value</u>		<u>Fair value</u>	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Shares traded in the stock market –Acquisition cost (see cash flows from investing activities)	2.000	-	2.000	-
Loss that arose from valuation at 30/9/2013 (see note 9)	(601)	-	(601)	-
Traded warrants - Valuation at 30/9/2013 (see note 9)	403	-	403	-
	1.801	-	1.801	-

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

20. CASH AND CASH EQUIVALENTS:

The cash and cash equivalents are analyzed as follows:

	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Cash in hand	514	505	498	495
Deposits (sight and time)	3.255	69.020	2.706	68.449
	3.769	69.524	3.205	68.944

The bank deposits are lent at interest with floating interest rates based on the monthly interest rates of bank deposits and mainly refer to deposits in euro. Group's bank deposits in other currencies in 30th September 2013 amount to € 110 (Group's bank deposits in other currencies in 31st December 2012 amounted to € 192). The income from sight and time bank deposits interest is recognized in accrual basis of accounting. (See note 9).

21. SHARE CAPITAL:

The share capital of the Company in 30th September 2013, consists of 86.735.980 common nominal shares, with nominal value € 0,31 each.

The Company's shares are publicly traded on the Athens Stock Exchange.

According to the Shareholders Record of the Company, in the 30th of September 2013, the shareholders with holding a percentage in the Company greater than 2 % were the following:

	Number of shares acquired	% 30th September 2013
G. Apostolopoulos Holdings S.A.	31.665.727	36,51%
Asklepios International GmbH	26.649.532	30,73%
Eurofinanciere D Investissement Monaco	2.585.057	2,98%
Credit Suisse-AG	6.715.361	7,74%
Free float < 2%	19.120.303	22,04%
	86.735.980	100,00%

The share premium of the Company resulted from the period of 1991 until the period of 2007, with a total amount of € 19.777 by the issuing of shares against cash, in value greater than their nominal value.

22. LEGAL, TAX FREE AND SPECIAL RESERVES:

The legal, tax free and special reserves are analyzed as follows:

The Group

	<u>30/9/2013</u>	<u>31/12/2012</u>
Legal reserve	5.537	5.537
Tax free and specially taxed reserves	75.151	75.151
Other	(61)	(81)
	80.627	80.607

The Company

	<u>30/9/2013</u>	<u>31/12/2012</u>
Legal reserve	5.026	5.026
Tax free and specially taxed reserves	74.891	74.891
Other	440	440
	80.356	80.356

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Legal Reserve: According to the Greek Company law, the companies are obliged to form at least 5% of their annual net profits, as they are represented in the accounting books, in legal reserve, until the accumulated amount of the legal reserve reaches at least the 1/3 of the capital share. The above-mentioned reserve cannot be distributed during the operation of the Company.

Tax free and Specially Taxed Reserves: The untaxed and specially taxed reserves represent interest income, which are tax free or taxed by 10% at their source. The particular income is not taxable under the condition that adequate profits exist, from which respective untaxed reserves can be formed. According to the Greek tax legislation, this reserve is excluded from income tax, under the condition that it will not be distributed to the shareholders. The Company does not intend to distribute the particular reserve and thus it has not proceeded to the estimation of deferred income tax that would have been necessary in the case of reserve distribution.

Special Reserves: The special reserves have been formed based on the decisions of the shareholders' General Assemblies. The Company does not intend to distribute the particular reserves.

The special reserve included in the tax free and specially taxed reserves, at 31st December 2012 and at 30th September 2013 amounted to € 4.343 in Company and € 4.437, in Group, was formed according to the provisions of L. 3697/2008. The tax liability which will accumulate due to the distribution of this special reserve is estimated, at 30th September 2013 in € 1.129 for the Company and € 1.154 for the Group and will be recognized, if only its distribution takes place.

23. LOANS:

	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Non-current loans				
Common bond loan	126.406	146.808	126.406	146.808
Finance leases	268	1.048	104	830
	126.674	147.856	126.511	147.638
Current loans				
Bank loans	11.347	13.599	9.097	11.349
Non-current loans payable within the next 12 months	28.693	16.322	28.693	16.322
Factoring	391	832	391	832
Finance leases	1.272	1.749	1.193	1.636
	41.703	32.502	39.374	30.139
Total of loans due	168.377	180.358	165.885	177.777
	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Maturity of non-current loans				
Up to 1 year	-	-	-	-
Between 1 & 5 years	126.406	146.808	126.406	146.808
Over 5 years	-	-	-	-
	126.406	146.808	126.406	146.808

The fair value of borrowings approaches their book value, as Group's and Company's borrowings are mainly based on floating rates.

On July 12, 2012 the company has signed the Common Bond Loan Issuance Programme, according to the provisions of C.L. 2190/1920 and L. 3156/2003, through private placement to NATIONAL BANK OF GREECE S.A., EFG EUROBANK ERGASIAS S.A. and ALPHA BANK S.A., the last acting also as a "Manager", of total nominal value of up to € 164.000 and granting of collaterals, following the decision of the 1st Repetitive Assembly of the Shareholders on 21st March 2012 and the decision of the Board of Directors on July 11, 2012.

The Loan's duration is 5 years with floating rate based on Euribor plus margin and is payable in ten (10) installments. The Common Bond Loan was used as follows: i) Refinancing of the 24 May 2007 existing Bond Loan of € 150.000 and remaining to be paid amount of € 144.000, ii) Refinancing of the company's existing short-term borrowings of € 9.000 to bond holder banks, and iii) the remaining amount of € 11.000 will be used in order to cover general business purposes and needs.

The financial clauses of the Loan include presuppositions of minimum Net Debt, minimum proportion of Net Debt to EBITDA, EBITDA to the total amount of interest expenses minus interest income, total Bank Debt to the total Bank Debt plus Equity.

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The current bank loans, except the common Bond Loan (long term liabilities payable in the next year), have been received by the Company and its subsidiaries for serving their needs in working capital.

The loan cost has charged the period's results according to accrual basis principle (Note 9).

The liabilities that result from leases concern the leasing of mechanical – hospital equipment. The liabilities to the lessor are analyzed as follows:

Leasing Liabilities - Minimum payments of leases:

	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Until one year	1.309	1.827	1.214	1.694
Between 1 & 5 years	282	1.087	104	842
After 5 years	0	0	0	0
Total	1.591	2.914	1.319	2.536
Future finance charges on finance leases	(51)	(117)	(21)	(70)
Present value of lease liability	1.540	2.797	1.298	2.466

The present value of the leasing liabilities is the following:

	The Group		The Company	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Up one year	1.272	1.749	1.193	1.636
From 1 to 5 years	268	1.048	104	830
After 5 years	0	0	0	0
	1.540	2.797	1.298	2.466

Over the leased assets ownership retention exists, which will stay in force until the ending of the leasing period and the payment in full of the leases.

There are no other guaranties and commitments of ownership or use over the fixed assets and the other assets of the Group except the one mentioned in note 12.

24. GOVERNMENT GRANTS:

The movement in the government grants during the period ended in 30th September 2013 and the year ended in 31st December 2012 was the following:

	<u>The Group</u>	<u>The Company</u>
Balance 01.01.2012	22	-
Additions	-	-
Depreciation	-	-
Balance 31.12.2012	22	-

	<u>The Group</u>	<u>The Company</u>
Balance 01.01.2013	22	-
Additions	-	-
Deletion	21	-
Depreciation	-	-
Balance 30.9.2013	1	-

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

25. PROVISION FOR RETIREMENT INDEMNITIES:

(a) Government Insurance Programs: The contributions of the Company and the Group to the insurance funds for the period ended in 30th September 2013, were recognized as expenses and amounted to € 10.281 and € 10.614 respectively.

(b) Provision for retirement indemnities: According to the Greek employment legislation, the employees entitled to receive compensation in case of dismissal or retirement, the amount of which varies depending on the salary, the years of service and the type of retirement (dismissal or pensioning) of the employee. Employees that resign or get dismissed with a justification are not entitled to receive compensation. The payable compensation in case of retirement equals the 40% of the compensation that would have been payable in case of an unjustified dismissal. In Greece, according to the local practice, these programs are not granted. The Company debits to the results for the accrued benefits in every period with a relevant rise of the pensioning liability. The payments of the benefits performed to the pensioners every period are charged against this liability.

The movement of the net liability in the accompanying balance sheets of the Company and the Group is the following:

The Company	<u>30th September</u>	<u>31st December</u>
	<u>2013</u>	<u>2012</u>
Net liability at the beginning of the year	11.572	18.853
Adjustement due to retrospective application of revised IAS 19	-	(4.969)
Net liability at the beginning of the year (*)	11.572	13.884
Actual benefits paid by the Company	(596)	-
Expense recognized in the income statement (Note 5)	1.070	-
Income from reversal of formed provisions – net effect (*)	-	(2.312)
Net liability at the end of the period/year (*)	12.046	11.572

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

The Group	<u>30th September</u>	<u>31st December</u>
	<u>2013</u>	<u>2012</u>
Net liability at the beginning of the year	11.633	19.111
Adjustement due to retrospective application of revised IAS 19	-	(4.969)
Net liability at the beginning of the year (*)	11.633	14.142
Actual benefits paid by the Company	(596)	-
Expense recognized in the income statement (Note 5)	1.076	-
Income from reversal of formed provisions – net effect (*)	-	(2.509)
Net liability at the end of the period/year (*)	12.113	11.633

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

An international firm of independent analogists/actuaries evaluated the Company's liabilities arising from the obligation to pay retirement indemnities.

The details and principal assumptions of the actuarial study as at 30th of September 2013 and 31st of December 2012 is the following:

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	<u>the Group</u>		<u>the Company</u>	
	<u>30th</u> <u>September</u> <u>2013</u>	<u>31st</u> <u>December</u> <u>2012(*)</u>	<u>30th</u> <u>September</u> <u>2013</u>	<u>31st</u> <u>December</u> <u>2012(*)</u>
Present Value of unfunded obligations	-	11.633	-	11.572
Unrecognized actuarial net (loss) / gains	-	2.210	-	2.234
Net liability in Balance Sheet	-	13.843	-	13.806
Adjustement due to retrospective application of revised IAS 19	-	(2.210)	-	(2.234)
Net liability in Balance Sheet (*)	-	11.633	-	11.572
Components of net periodic pension cost:				
Service cost	744	1.214	740	1.180
Past service cost	-	(5.054)	-	(5.054)
Interest cost	332	610	330	608
Actuarial (losses) / gains	-	2.073	-	2.048
Employment termination cost	-	(196)	-	52
Regular charge to operations/results	1.076	(1.353)	1.070	(1.166)
Additional cost (benefit) of extra benefits	-	-	-	-
Total charge to operations/results	1.076	(1.353)	1.070	(1.166)
Reconciliation of benefit obligation:				
Net liability at beginning of period	11.633	14.142	11.572	13.884
Service cost	744	1.214	740	1.180
Past service cost	-	(5.054)	-	(5.054)
Interest cost	332	610	330	608
Benefits paid	(596)	(1.156)	(596)	(1.146)
Additional cost (benefit) of extra benefits and employment termination cost	-	(196)	-	52
Actuarial (losses) / gains	-	2.073	-	2.048
Present value of obligation at the end of the year / period	12.113	11.633	12.046	11.572

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

Group

Principal assumptions:	2012
Discount rate	3,6%
Rate of compensation increase	3,0%
Increase in consumer price index	2,0%

Company

Principal assumptions:	2012
Discount rate	3,6%
Rate of compensation increase	3,0%
Increase in consumer price index	2,0%

The additional cost of extra benefits relates to benefits paid to employees, who became redundant. Most of these benefits were not expected within the terms of this plan and accordingly, the excess of benefit payments over existing reserves have been treated as an additional pension charge.

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Retrospective application of revised standard IAS 19 “Employee Benefits”

The adoption of the revised standard IAS 19 has been applied retrospectively since 1st January 2012 (31/12/2011) and according the provisions of **IAS 8 “Accounting policies, changes in Accounting estimates and errors ”**. The effects of this change in this accounting policy are mentioned below:

Income Statement for the period ended September 30, 2012

The Group	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Cost of sales	(130.146)	330	(129.816)
Gross Profit	43.670	330	43.999
Administrative expenses and Distribution Costs	(27.430)	70	(27.360)
Other income/ (expenses)	2.558	3.322	5.880
PROFIT / (LOSS) BEFORE TAX	10.574	3.721	14.295
Income Tax Expense	(4.443)	(745)	(5.188)
PROFIT / (LOSS)	6.131	2.976	9.107
Attributable to: Equity holders of the Parent Company	5.971	2.977	8.948
Earnings / (losses) per Share (in Euro) Basic	0,07	0,03	0,10
The Company	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Cost of sales	(126.694)	330	(126.364)
Gross Profit	43.352	330	43.682
Administrative expenses and Distribution Costs	(24.562)	69	(24.493)
Other income/ (expenses)	2.664	3.270	5.934
PROFIT / (LOSS) BEFORE TAX	13.431	3.670	17.101
Income Tax Expense	(4.381)	(734)	(5.115)
PROFIT / (LOSS)	9.051	2.934	11.985
Attributable to: Equity holders of the Parent Company	9.051	2.934	11.985
Earnings / (losses) per Share (in Euro) Basic	0,10	0,04	0,14

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Comprehensive Income Statement for the period ended September 30, 2012

The Group	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Recognized actuarial gains/(losses) related to provision for retirement indemnities	-	(1.554)	(1.554)
Income tax relating to items of other comprehensive income	-	311	311
Other comprehensive income after tax (b):	-	(1.243)	(1.243)
Other comprehensive income / (loss) after tax:	6.130	1.733	7.863
Attributable to:			
Owners of the Parent	5.970	1.733	7.703
The Company	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Recognized actuarial gains/(losses) related to provision for retirement indemnities	-	(1.536)	(1.536)
Income tax relating to items of other comprehensive income	-	307	307
Other comprehensive income after tax (b):	-	(1.229)	(1.229)
Other comprehensive income / (loss) after tax:	9.051	1.705	10.756
Attributable to:			
Owners of the Parent	9.051	1.705	10.756

The adoption of revised standard IAS19 resulted to the increase of profit before taxes, financing and investing activity and depreciation of € 3.720 for Group and € 3.669 for Company.

Statements of Financial Position as of 31 December 2011 and 31 December 2012

31 December 2011

The Group	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Deferred tax assets	6.542	(993)	5.549
TOTAL ASSETS	470.785	(993)	469.792
Retained Earnings	10.414	3.975	14.389
Total equity	137.900	3.975	141.875
Provision for retirement indemnities	19.111	(4.969)	14.142
TOTAL EQUITY AND LIABILITIES	470.785	(993)	469.792

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

The Company	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Deferred tax assets	6.481	(993)	5.487
TOTAL ASSETS	489.158	(993)	488.164
Retained Earnings	34.841	3.975	38.817
Total equity	161.863	3.975	165.838
Provision for retirement indemnities	18.853	(4.969)	13.884
TOTAL EQUITY AND LIABILITIES	489.158	(993)	488.164

31 December 2012

The Group	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Deferred tax assets	8.258	(442)	7.816
TOTAL ASSETS	504.008	(442)	503.567
Retained Earnings	3.105	1.769	4.874
Total equity	130.708	1.769	132.477
Provision for retirement indemnities	13.843	(2.210)	11.633
TOTAL EQUITY AND LIABILITIES	504.008	(442)	503.567

The Company	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Deferred tax assets	8.247	(447)	7.800
TOTAL ASSETS	522.554	(447)	522.107
Retained Earnings	20.624	1.788	22.412
Total equity	147.646	1.788	149.433
Provision for retirement indemnities	13.806	(2.234)	11.572
TOTAL EQUITY AND LIABILITIES	522.554	(447)	522.107

Statement of changes in equity for the period ended September 30, 2012

The adoption of revised standard IAS19 resulted to the increase of equity attributable to owners of the parent as well as of total equity of € 5.707 (3.975 plus 1.732) for Group and € 5.681 . (3.975 plus 1.706) for Company.

Cash Flow Statement for the period ended September 30, 2012

The Group	Before the adjustment	Adoption of the revised standard IAS 19	After the adjustment
Period's profit / (loss) before taxation	10.574	3.721	14.295
Provision for retirement indemnities (plus actuarial gains/ losses)	250	(3.721)	(3.470)

The Company **Adoption of the revised**

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	Before the adjustment	standard IAS 19	After the adjustment
Period's profit / (loss) before taxation	13.431	3.669	17.100
Provision for retirement indemnities (plus actuarial gains/ losses)	399	(3.669)	(3.270)

26. TRADE ACCOUNTS PAYABLE:

The trade accounts payable are analyzed as follows:

	<u>the Group</u>		<u>the Company</u>	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Suppliers	73.252	88.199	85.788	99.205
Checks outstanding and bills payable (postdated)	11.337	5.552	9.016	5.261
	84.589	93.751	94.804	104.466

27. ACCRUED AND OTHER CURRENT LIABILITIES:

The amount represented in the accompanying balance sheet is analyzed as follows:

	<u>The Group</u>		<u>The Company</u>	
	<u>30/9/2013</u>	<u>31/12/2012</u>	<u>30/9/2013</u>	<u>31/12/2012</u>
Customers' advances	0	0	0	0
Obligations to associates	34	34	34	34
Sundry creditors	9.325	27.312	6.342	24.320
Insurance and pension contributions payable	8.436	15.794	6.244	13.442
Accrued expenses	6.215	4.746	5.876	4.369
Dividends payable	13	13	13	13
Other provisions	209	209	0	0
Other	896	1.087	886	1.078
	25.128	49.195	19.395	43.256

28. OPERATING SEGMENT REPORTING – SEASONALITY OF INTERIM BUSINESS OPERATIONS :

A) The group in year 2009 replaces **IAS 14 «Segment reporting»** with **I.F.R.S. 8 «Operating segment reporting»**. According to I.F.R.S. 8 the definition of operating segments is based on «management approach» while the standard requires the report of group's information based on internal organizational and managerial structures, related to operating segments.

The operating segment performance assessment is based on revenue, operating results and EBITDA. (results before taxes, financing, investing activity and depreciation), while intersegment sales are eliminated in consolidated financial statements. Group applies the same accounting policies for segment performance measurement, with the ones of the financial statements.

Hence the group's operating segments are the following: a) Domestic healthcare service, b) Healthcare service provided abroad (Romania) and c) Sale of medical tools & sanitary/health equipment.

The sales and results of group's operating segments for periods 1/1-30/9/2013 and 1/1-30/9/2012 are the following:

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

A' nine months 2012(*)

	Domestic healthcare service	Healthcare service provided abroad	Sale of medical tools & sanitary/health equipment	Other	Eliminations	Total
<u>Sales</u>						
To customers	170.365	3.344	106	-	-	173.815
Intersegment	771	-	7.771	-	(8.542)	0
Total	171.136	3.344	7.877	-	(8.542)	173.815

Results

Profit before taxes, financing and investing activity and depreciation	30.463	89	403	(30)	-	30.926
Profit before taxes	14.524	(158)	(5)	(30)	(37)	14.295

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

A' nine months 2013

	Domestic healthcare service	Healthcare service provided abroad	Sale of medical tools & sanitary/health equipment	Other	Eliminations	Total
<u>Sales</u>						
To customers	129.872	3.301	68	32	-	133.273
Intersegment	285	-	5.353	17	(5.655)	0
Total	130.157	3.301	5.421	49	(5.655)	133.273

Results

Profit before taxes, financing and investing activity and depreciation	12.839	(10)	607	(10)	-	13.426
Profit before taxes	(643)	(245)	317	302	(33)	(301)

Group's operating segment assets and liabilities for the period 1/1-30/9/2013 and year 2012 are the following:

	Domestic healthcare service	Healthcare service provided abroad	Sale of medical tools & sanitary/health equipment	Other	Eliminations	Total
<u>Assets in</u>						
30 th September 2013	471.670	1.458	34.620	11.209	(67.670)	451.287
31 st December 2012 (*)	524.773	1.732	39.090	11.110	(73.139)	503.567

(*) Adjusted due to retrospective application of revised IAS 19 (Note 25)

B) The Company's and Group's operation has intense seasonality in the third quarter of each year, when the turn over is significantly decreased in relation to the rest of the other quarters.

29. RELATED PARTY DISCLOSURES:

The Company and its subsidiaries are related to the following legal and natural persons:

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

- ▶ with Mr. Georgios Apostolopoulos and the legal persons or other business activities he is related with, due to the majority of shares acquisition in its capital
- ▶ with its subsidiaries including their main shareholders and the members of their Boards of Directors
- ▶ with the members of the Company's Board of Directors

The transactions with its subsidiaries are mainly concerning the provision of commercial services, as well as the purchasing and selling of goods. The transactions are realized within the normal operating framework of the Company.

The relative balances receivable from associates are not covered by securities, mortgages and their payment in full is conducted by cash payment within the time limits agreed between the companies in question. The Management of the Company does not regard that a provision/allowance for a possible non-collection of its subsidiaries related receivables is needed, hence no provision/allowance for doubtful debtors against these receivables is formed, except the case of subsidiary Ortelia (Note 18) and associate company LAVIE ASSURANCE.

The balances receivable/(payable) of the related party accounts of the Group are as follows:

Year 2013

Subsidiaries

	Company		Income for the period 1/1-30/9/2013	Purchases for the period 1/1-30/9/2013
	Receivables at 30/9/2013	Liabilities at 30/9/2013		
<i>ATHENS MEDICAL CENTER S.A.</i>	0	0	0	0
<i>IATRIKI TECHNIKI S.A.</i>	11	30.769	11	5.353
<i>EREVNA S.A.</i>	0	31	0	0
<i>AXONIKI EREVNA S.A.</i>	0	0	0	0
<i>PHYSIOTHERAPY CENTER S.A.</i>	0	300	86	285
<i>MEDSANA BUCHAREST MEDICAL CENTER</i>	0	0	0	0
<i>BIOAXIS SRL (ex MEDSANA SRL)</i>	0	0	0	0
<i>ORTELIA HOLDINGS</i>	1.745	0	0	0
<i>EUROSITE</i>	3.413	24	38	17
<i>GALA</i>	459	(97)	1	53
<i>HOSPITAL AFFILIATES INTERNATIONAL S.A.</i>	375	0	0	0
TOTAL	6.003	31.026	136	5.708

Part of the Company's receivables from subsidiaries Eurosite S.A. and Gaia S.A. and specifically receivables amounted to euro 1.548 and euro 252 respectively, refer to deposits of the Parent Company for the purpose of future share capital increase of these subsidiaries. The rest of the receivables of the above mentioned companies, as well as the receivables from Ortelia refer to financial facilitation. Especially regarding the receivables of euro 1.745 from Ortelia, the Company formed provision for impairment loss amounted to 1.729 euro, charging previous year's 2011 results. Furthermore, in the year 2012, the company in relation to receivables from **LAVIE ASSURANCE** of 1.745 euro (in 30/9/2013), formed provision for impairment loss of 909 euro, charging its results.

The purchases of the Company mainly refer to purchases of medical materials from IATRIKI TECHNIKI S.A. transacted in the normal course of business. Liabilities exist due to this commercial relationship.

Purchases from PHYSIOTHERAPY CENTER S.A. refer to health services that were provided by the subsidiary to patients of the Group's Clinics.

Also Parent Company has guaranteed in favour of subsidiary Gaia S.A. for its borrowings (financial leases) amounted to € 41 , as well as in favour of the subsidiary Medsana up to the amount of € 169.

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	Company <i>Receivables from dividends at 30/9/2013</i>	<i>Income from dividends for the period 1/1-30/9/2013</i>
<i>IATRIKI TECHNIKI S.A.</i>	-	-
<i>MEDSANA BUCHAREST MEDICAL CENTER</i>	-	-
<i>PHYSIOTHERAPY CENTER S.A.</i>	-	33
TOTAL	-	33

Associates- Other

	The Group				The Company			
	<i>Receivables at 30/9/2013</i>	<i>Liabilities at 30/9/2013</i>	<i>Income for the period 1/1- 30/9/2013</i>	<i>Purchases for the period 1/1- 30/9/2013</i>	<i>Receivables at 30/9/2013</i>	<i>Liabilities at 30/9/2013</i>	<i>Income for the period 1/1- 30/9/2013</i>	<i>Purchases for the period 1/1- 30/9/2013</i>
<i>G. APOSTOLOPOULOS Holdings</i>	0	0	0	0	0	0	0	0
<i>IKODOMIKI EKMETALEFTIKI S.A.</i>	4	0	0	0	3	0	0	0
<i>LA VIE Assurance SYCHRONI ECHODIAGNOSI</i>	1.745	39	13	5	1.745	39	13	5
<i>PROSTATE INSTITUTE KORINTHIAKOS RYTHMOS</i>	0	27	0	0	0	27	0	0
<i>HERODIKOS Ltd QUS ATH. CENTER OF ENVIRONMENT</i>	0	0	0	0	0	0	0	0
<i>TRADOR S.A. AGGEOLOGIKI DIEREVNISI S.A.</i>	6	408	0	247	6	68	0	185
<i>ATHENS PAEDIATRICS CENTER ELECTRONYSTAGMOG RAFIKI S.A. NEVROLITOURGIKI S.A.</i>	0	0	0	0	0	0	0	0
<i>MEDISOFT</i>	0	0	0	0	0	0	0	0
<i>MEDICAFE CATERING SERVICES S.A.</i>	1	0	0	0	1	0	0	0
<i>DOMINION INSURANCE BROKERAGE S.A.</i>	6	0	49	0	6	0	49	0
<i>INTEROPTICS SA</i>	0	67	0	14	0	63	0	14
	1.788	548	62	265	1.787	204	62	203

	The Group		The Company	
	<i>Receivables from dividends at 30/9/2013</i>	<i>Income from dividends for the period 1/1- 30/9/2013</i>	<i>Receivables from dividends at 30/9/2013</i>	<i>Income from dividends for the period 1/1- 30/9/2013</i>
<i>MEDICAFE CATERING SERVICES S.A.</i>	38	38	-	-

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

	The Group	The Company
Compensations of executives and members of the Board for the period 1/1-30/9/2013	3.964	3.463

	The Group	The Company
Receivables from executives and members of the Board at 30/9/2013	0	0
Liabilities to executives and members of the Board at 30/9/2013	1.044	991

Year 2012

Subsidiaries

	Company			
	<i>Receivables at 31/12/2012</i>	<i>Liabilities at 31/12/2012</i>	<i>Income for the period 1/1-30/9/2012</i>	<i>Purchases for the period 1/1-30/9/2012</i>
ATHENS MEDICAL CENTER S.A.	0	0	0	0
IATRIKI TECHNIKI S.A.	0	34.802	11	7.771
EREVNA S.A.	0	31	0	0
AXONIKI EREVNA S.A.	0	0	0	0
PHYSIOTHERAPY CENTER S.A.	377	775	169	672
MEDSANA BUCHAREST MEDICAL CENTER	0	0	0	0
BIOAXIS SRL (ex MEDSANA SRL)	0	0	0	0
ORTELIA HOLDINGS	1.745	0	0	0
EUROSITE	3.616	3	0	0
GAIA SA	206	305	0	1.594
HOSPITAL AFFILIATES INTERNATIONAL S.A.	364	0	0	0
TOTAL	6.308	35.916	180	10.037

	Company	
	<i>Receivables from dividends at 31/12/2012</i>	<i>Income from dividends for the period 1/1-30/9/2012</i>
IATRIKI TECHNIKI S.A.	-	-
PHYSIOTHERAPY CENTER S.A.	25	33
TOTAL	25	33

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

Associates- Other

	The Group				The Company			
	<i>Receivables at 31/12/2012</i>	<i>Liabilities at 31/12/2012</i>	<i>Income for the period 1/1- 30/9/2012</i>	<i>Purchases for the period 1/1- 30/9/2012</i>	<i>Receivables at 31/12/2012</i>	<i>Liabilities at 31/12/2012</i>	<i>Income for the period 1/1- 30/9/2012</i>	<i>Purchases for the period 1/1- 30/9/2012</i>
G. APOSTOLOPOULOS HOL.	0	0	0	0	0	0	0	0
IKODOMIKI EKMETALEFTIKI S.A.	5	0	0	0	3	0	0	0
LA VIE Assurance SYCHRONI ECHODIAGNOSI	1.756	34	172	9	1.756	34	172	9
PROSTATE INSTITUTE KORINTHIAKOS RYTHMOS	0	27	0	0	0	27	0	0
HERODIKOS Ltd QUS ATH. CENTER OF ENVIRONMENT	0	0	0	0	0	0	0	0
TRADOR S.A. AGGEIOLOGIKI DIEREVNISI S.A.	27	0	0	0	27	0	0	0
ATHENS PAEDIATRICS CENTER	0	7	0	0	0	7	0	0
ELECTRONYSTAGMOG RAFIKI S.A. NEVROLITOURGIKI S.A.	0	0	0	0	0	0	0	0
MEDISOFT	0	0	0	0	0	0	0	0
MEDICAFE CATERING SERVICES S.A.	0	0	0	0	0	0	0	0
DOMINION INSURANCE BROKERAGE S.A.	20	0	52	0	20	0	52	0
INTEROPTICS S.A.	0	0	0	0	0	0	0	0
TOTAL	1.814	443	224	270	1.812	168	224	206

	The Group		The Company	
	<i>Receivables from dividends at 31/12/2012</i>	<i>Income from dividends for the period 1/1- 30/9/2012</i>	<i>Receivables from dividends at 31/12/2012</i>	<i>Income from dividends for the period 1/1- 30/9/2012</i>
MEDICAFE CATERING SERVICES S.A.	-	42	-	-

	The Group	The Company
Compensations of executives and members of the Board for the period 1/1-30/9/2012	4.208	3.725

	The Group	The Company
Receivables from executives and members of the Board at 31/12/2012	-	-
Liabilities to executives and members of the Board at 31/12/2012	3.177	3.125

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

30. LEGAL DISPUTES - CONTINGENCIES AND COMMITMENTS :

(a) Lawsuits/Litigation and claims:

The Company is involved (in its capacity as defendant and as plaintiff) in various lawsuits and legal amperages in the framework of its normal operation. The Management, as well as its legal advisors estimates that all the pending cases are expected to be settled without any significant negative repercussions on the consolidated financial position of the Company or in the results of its operation.

(b) Commitments:

(i) Commitments from operational leases:

The 30th of September 2013 the Group and the Company had various agreements of operational lease, concerning the renting of buildings and transportation equipment and they end in several dates.

The renting expenses are included in the accompanying consolidated income statement of the period ended in the 30th of September 2013 and they amount to € 1.403 (€1.475 at 30th of September 2012).

The minimum future payable rental leases based on non-reversible contracts of operational leases of 30th of September 2013 and 31st December 2012 are as follows:

	31/12/2012	
Commitments from operational leases:	<u>The Group</u>	<u>The Company</u>
Within one year	1.626	1.786
1-5 years	6.025	6.100
After 5 years	14.968	14.967
	22.619	22.853

	30/9/2013	
Commitments from operational leases:	<u>The Group</u>	<u>The Company</u>
Within one year	1.718	1.743
1-5 years	6.113	6.191
After 5 years	14.624	14.624
	22.455	22.558

(ii) Guarantees:

The Group in 30th of September 2013 had the following contingent liabilities:

Had issued letters of guarantee for good performance for a total amount of € 157 (€161 in year 2012).

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

31. SUBSEQUENT EVENTS:

In 8th August 2013 the Greek Company “**G.Apostolopoulos Holdings S.A.**” submitted optional public offer in order to acquire the total number of shares, of parent company “**Athens Medical Center S.A.**”. After the expiration of acceptance period the Greek Company “**G.Apostolopoulos Holdings S.A.**” owns directly and indirectly the percentage of approximately 38,88% on the deposited share capital and voting rights of parent company “**Athens Medical Center S.A.**”.

The expiration date of bonds amounted to €8.161thous. of common bond loan issuance program, is extended from 2/10/2013 to 19/1/2014 after the consensus of bond holders – borrowers.

According to the no. Y9/fin.77307/14.08.2013 (FEK B’ 2045/22.08.2013) decision of Minister of Health Sector, the provisions of article 100 par.5 of L.4172/2013 (FEK. A’ 167/23.07.2013) and the Minister’s Decision of No. Y9/Fin.91813(FEK B’ 2511/7.10.2013) the amounts for the Rebate and the Clawback, related to the submitted invoices from our Clinics to EOPYY, have been determined.

No further provisions for credit notes have been formed in the Interim Financial Statements for the period 1/1 – 30/9/2013, because our Company does not acknowledge neither the accuracy of these amounts, nor the legal basis of EOPYY’s decision.

For these reasons, our Company has taken legal actions either as a standalone entity, or as part with other Clinics, requesting the annulment of these decisions. The above mentioned request will be discussed at 17/12/2013 as S.t.E. accepts the relevant preferable appeal.

Maroussi, 27/11/2013

*THE PRESIDENT OF
THE BOD*

*THE CHIEF
EXECUTIVE OFFICER
AND MEMBER OF THE
BOD*

*THE GENERAL GROUP
CFO*

THE PARENT CFO

*THE PARENT CHIEF
ACCOUNTANT*

*GEORGIOS V.
APOSTOLOPOULOS*

*VASSILIOS G.
APOSTOLOPOULOS*

*EMMANOUIL P.
MARKOPOULOS*

*PETROS D.
ADAMOPOULOS*

PANAGIOTIS CH. KATSICHTIS

ID AK 038305

ID Ε 350622

ID Π 001034

ID AZ 533419

*ID AB 052569
O.E.E. Rank No.17856
Classification A’*

ATHENS MEDICAL CENTER S.A.
INTERIM FINANCIAL STATEMENTS (1st JANUARY TO 30th SEPTEMBER 2013)
(Amounts in all tables and notes are presented in thousands of Euro, unless otherwise stated)

32. WEB SITE ADDRESS:

The Company's interim financial statements, consolidated and separate, are uploaded to the internet address www.iatriko.gr.

IMPORTANT NOTE: These financial statements and notes have been translated to English language from the original statutory Greek financial statements and notes. In case that differences exist between this translation and the Greek financial statements and notes, the Greek financial statements and notes will prevail.